| アブストラクト | Pembrolizumab and nivolumab are PD-1 monoclonal antibodies which promote cell death, augmenting the immune response against malignancy. These agents are primary therapies for treatment of advanced melanoma, among other malignancies; therapy toxicities can lead to patient discontinuation especially in immune-related adverse events (irAEs)(1,2) . We aimed to examine the risk of adverse events for these two PD-1 inhibitors since FDA approval December 2014, using the FDA Adverse Event Reporting System (FAERS) database, and determine whether the risk of these adverse events differ from clinical trial (RCTs) data. |
|---|
| ジャーナル名 | Journal of the European Academy of Dermatology and Venereology : JEADV |
|---|
| 投稿日 | 2021/5/21 |
|---|
| 投稿者 | Gupta, N; Cullison, C; Mally, A; Xiang, L; Hill, S T; Beveridge, M G |
|---|
| 組織名 | Case Western Reserve University School of Medicine, Cleveland.;Department of Dermatology, University Hospitals Cleveland Medical Center,;Cleveland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34014567/ |
|---|
